NCCN Guidelines for Metastatic Breast Cancer Management
For metastatic breast cancer, treatment is stratified by molecular subtype: HR+/HER2- disease should receive endocrine therapy plus CDK4/6 inhibitors as first-line (palbociclib + letrozole or fulvestrant is Category 1); HER2+ disease requires pertuzumab + trastuzumab + taxane as preferred first-line therapy; and triple-negative disease should receive immunotherapy + chemotherapy if PD-L1 positive, or single-agent chemotherapy if PD-L1 negative. 1
HR-Positive/HER2-Negative Metastatic Disease
First-Line Therapy
Postmenopausal women: Aromatase inhibitors (AIs) combined with CDK4/6 inhibitors are the standard approach
Premenopausal women: Require ovarian suppression/ablation plus hormonal therapy, as contemporary agents were studied only in postmenopausal populations 2
Key Principle
Endocrine therapy is preferred over chemotherapy except in cases of rapidly progressive visceral disease or organ dysfunction 2. Starting with chemotherapy provides no survival advantage and increases toxicity.
Second-Line and Beyond
- Sequential hormone therapy should continue until unequivocal progression 2
- Fulvestrant + palbociclib (Category 1) for progression on prior AIs, based on PALOMA-3 showing median PFS 9.2 vs 3.8 months (HR 0.42) 3
- Exemestane + everolimus for progression on nonsteroidal AIs (improves PFS but not OS) 2
Critical Caveat
CDK4/6 inhibitors cause significant neutropenia (79.5% with palbociclib + letrozole). Monitor blood counts every 14 days for first two cycles, then at each cycle start. Manage with dose delays/reductions 1. Despite hematologic toxicity, febrile neutropenia remains rare (0.6%) 3.
HER2-Positive Metastatic Disease
First-Line Therapy (Preferred)
Pertuzumab + trastuzumab + docetaxel is the Category 1 standard, offering survival benefit over trastuzumab + chemotherapy alone 4, 5. This triple combination is mandatory for de novo and visceral-dominant disease 2.
Alternative First-Line Options
- T-DM1 (ado-trastuzumab emtansine) ± pertuzumab: MARIANNE trial showed noninferior PFS (14.1-15.2 months) with better quality of life (median 7.7-9 months vs 3.9 months) 3, 4
- Use T-DM1 only when preferred regimen unsuitable due to better tolerability profile
- Grade 3-5 adverse events: 45-46% vs 54% with trastuzumab + taxane 4
After First-Line Progression
Continue HER2 blockade indefinitely - multiple trials demonstrate benefit of continuing trastuzumab beyond progression 4
Preferred subsequent options:
- T-DM1 (if not used first-line) 5
- Pertuzumab + trastuzumab (if pertuzumab-naive): ORR 24.2%, median PFS 15.5 months 4
- Trastuzumab + other chemotherapy
- Lapatinib + capecitabine
- Trastuzumab + lapatinib (without chemotherapy) 5
Critical Warning
Never combine trastuzumab with anthracyclines outside clinical trials - 27% rate of significant cardiac dysfunction is unacceptably high 4.
HR+/HER2+ Disease Specifics
Add HER2-targeted therapy to first-line AIs when chemotherapy not immediately indicated, as this improves PFS 2. For visceral-dominant disease, chemotherapy + HER2-targeted therapy provides survival benefit 2.
Triple-Negative Metastatic Disease
First-Line Therapy
PD-L1 status determines initial approach:
PD-L1 positive: Immunotherapy + chemotherapy
- Atezolizumab + nab-paclitaxel OR
- Pembrolizumab + chemotherapy 6
PD-L1 negative: Single-agent chemotherapy preferred over combination (unless symptomatic/life-threatening disease requiring rapid response) 6
- Platinum-based or non-platinum regimens based on individual assessment
Later Lines
- After ≥2 prior metastatic therapies: Sacituzumab govitecan (TROP2-directed ADC) 6
BRCA-Mutated TNBC
PARP inhibitors (olaparib or talazoparib) should be offered to germline BRCA1/2 mutation carriers no longer benefiting from prior therapy, rather than chemotherapy 6
Universal Principles Across All Subtypes
Monitoring
- Do not use tumor markers or circulating tumor cells alone to determine progression 2
- Require imaging, clinical examination, or disease-related symptoms for progression documentation 2
Treatment Duration
Continue therapy until unequivocal progression. Optimal duration of targeted therapies (trastuzumab, CDK4/6 inhibitors) in long-term responders remains unknown 2, 4.
Clinical Trial Enrollment
Strongly encourage participation at all treatment lines, including first-line setting 2, 1.
Genomic Testing
No routine role for genomic/expression profiling in selecting treatment for HR+ metastatic disease 2. Treatment selection should be based on clinical/pathologic features and validated biomarkers (HR, HER2, PD-L1, BRCA).
Special Considerations
- Recognize fertility loss issues in premenopausal women 2
- Account for menopausal status and ovarian estrogen production in treatment planning 2
- Balance efficacy against toxicity - combination targeted therapies (everolimus + exemestane, palbociclib + endocrine therapy) have more toxicity than single-agent endocrine options 2